血卟啉衍生物对鼻咽癌放射治疗效应观察  

THE CLINICAL OBSERVATION OF HPD ENHANCING RADIATION EFFECT ON NASOPHARYNGEAL CARCINOMA RADIOTHERAPY

作　　者：张恩罴[1] 夏云飞[1] 孙振权[1] 曾祥发[1] 罗国仪[1] 吴少雄[1] 

机构地区：[1]中山医科大学肿瘤防治中心放疗科

出　　处：《中山医科大学学报》1996年第1期32-36,共5页Academic Journal of Sun Yat-sen University of Medical Sciences

摘　　要：为了从临床观察血卟啉衍生物（ＨＰＤ）对鼻咽癌是否有加强放疗效应的作用，作者选取病理确诊１～Ⅳａ期初诊鼻咽癌９８例，按Ｔ、Ｎ、Ｍ和性别配对分为ＨＰＤ加放射组（实验组）和单纯放射组（对照组），均采用５０钴γ射线连续常规分割放射治疗。从鼻咽间接镜检查和ＣＴ扫描检查分析鼻咽原发灶的消退情况来看，实验组全消率分别为１００％，６５．３％，对照组全消率分别为７３．５％，３２．７％，两组差别有统计学意义（Ｐ＜０．０１）；颈部淋巴结转移灶，实验组全消率为９２．３％，明显高于对照组５９％（Ｐ＜０．０１）；计算ＨＰＤ的放射增敏比为１．４－１．５；两组急性放射反应和毒性反应无差别，说明血卟啉衍生物能提高鼻咽癌放疗的近期效应，配合放疗是安全的，远期疗效则有待观察。In order to observe whether hematoporphyrin derivatives (HPD ) may have a radiosensi- tive enhancement effect on nasopharyngeal carcinoma (NPC ) , the authors selected 98 consec- utive case which were diagnosed as NPC in I-IVa stages pathologically. Base on similar TNM staging and sex , these patients were equally distributed into HPD plus radiation group (ex- perimental group ) and radiation group (control group ) . All received continuous conventional fractionation of radiotherapy by 60 Co Y-ray. The result revealed that the total remission rates of primary NPC lesion , determined by the finding of indirect nasopharyngoscopy and CT scanning , were 100% and 65. 3% respectively in the experimental combined group as a whole , whereas those in the control group were 73. 5 % and 32. 7 % respectively. These dif- ferences between the two groups were of statistic significance , particularly in the remission rates of tumors in stages T3、4· The remission rate of metastatic neck tumor was 92. 3% in the experimental group ,a rate much higher than that 59% in the control group (P<0. 01 ). The radiosensitive enhancement ratio of HPD was calculated as 1. 4- 1 . 5. The acute radiation and toxic reaction did not differ significantly in these two groups. It shows that HPD may im- prove the short-term effect of radiotherapy of NPC and its use as a supplementary treatment has to be further investigated.

关 键 词：鼻咽癌 放射疗法 血卟啉衍生物 增敏作用 

分 类 号：R739.630.5[医药卫生—肿瘤]